Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials

Abstract

Patients with renal impairment are at higher risk of thrombosis and bleeding than those with normal renal function. The optimal rivaroxaban dose for thromboprophylaxis in acutely ill medical patients with renal impairment is unknown. MARINER and MAGELLAN were multicenter, randomized clinical trials of rivaroxaban in acutely ill medical patients. Efficacy and safety outcomes in patients with renal impairment in MARINER (7.5 mg once daily) were compared with those in patients with normal renal function in MARINER (10 mg once daily) and in a subpopulation of MAGELLAN that excluded patients at high risk for bleeding at baseline (10 mg once daily). Compared with enoxaparin/placebo in the MAGELLAN subpopulation, the relative risk (RR) of symptomatic venous thromboembolism (VTE) and VTE-related death with rivaroxaban 10 mg in patients with renal impairment (RR = 0.62; 95% confidence interval [CI] 0.27–1.44) was similar to that in those with normal renal function (RR = 0.78; 95% CI 0.44–1.40), while in MARINER, the 7.5 mg dose did not reduce the risk in patients with renal impairment (hazard ratio = 1.00; 95% CI 0.52–1.92). Major bleeding with rivaroxaban 10 mg once daily was higher in patients with renal impairment than in those with normal renal function in MAGELLAN (1.54% vs. 0.98%) and in the MAGELLAN subpopulation (0.94% vs. 0.61%). At a dose of 10 mg once daily, rivaroxaban is effective for thromboprophylaxis in acutely ill medical patients with impaired or normal renal function. The safety of this regimen is enhanced without loss of efficacy by excluding patients at high risk for bleeding, but not by using a reduced-dose strategy. Trial Registration ClinicalTrials.gov identifiers: NCT00571649 for the MAGELLAN trial, NCT02111564 for the MARINER trial.

A Comprehensive Review of Tocilizumab in COVID‐19 Acute Respiratory Distress Syndrome

“…The proposed mechanism of action of drug interactions is the effect on decreasing the effect of IL-6 and thus upregulation of transporters and drug metabolism enzymes. [85][86][87][88][89][90][91] Taken together, according to the limited data, administration 1 or 2 times of both intravenous and subcutaneous tocilizumab in the mentioned doses is considered safe in patients with severe/critical COVID-19; however, the tocilizumab safety data for other conditions should be considered in determining exclusion criteria in future clinical trials and practice.…”

Insidious development of pulmonary embolism in asymptomatic patients with COVID-19: Two rare case-reports

“…The natural course of SARS-CoV-2 viremia remains obscure as reinfections and/or recurrently positive RT-PCR results were previously described [ [43] , [44] , [45] , [46] ]. We have prescribed a new oral anticoagulant that may be useful in preventing future thromboembolic phenomena as SARS-CoV-2 reinfection and/or natural immunity remain obscure [ 26 , 27 ]. Currently, both patients are under follow-up to determine any side-effects of therapy (i.e., bleeding episodes).…”

“…She was discharged to home isolation. Oral rivaroxaban was prescribed for three months, and the patient is closely followed-up by her cardiologist [ 26 ].

Fig.

…”

Thrombolysis in severe COVID-19 pneumonia with massive pulmonary embolism

“…The patient was discharged to home isolation on hospital day 20 in good clinical condition. Oral Rivaroxaban was prescribed for three months [ 9 ].…”